HealthEquity, Inc. (NASDAQ:HQY) Stake Trimmed by Inspire Investing LLC

Inspire Investing LLC cut its position in shares of HealthEquity, Inc. (NASDAQ:HQY) by 12.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,715 shares of the company’s stock after selling 1,882 shares during the quarter. Inspire Investing LLC’s holdings in HealthEquity were worth $1,182,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Cape Investment Advisory Inc. acquired a new stake in shares of HealthEquity during the fourth quarter valued at approximately $27,000. Rise Advisors LLC purchased a new position in HealthEquity during the 1st quarter worth approximately $28,000. International Assets Investment Management LLC acquired a new stake in HealthEquity during the 2nd quarter valued at $35,000. YHB Investment Advisors Inc. purchased a new stake in shares of HealthEquity in the first quarter valued at $40,000. Finally, Fidelis Capital Partners LLC acquired a new stake in shares of HealthEquity in the first quarter worth $42,000. 99.55% of the stock is currently owned by institutional investors and hedge funds.

HealthEquity Stock Performance

HQY stock opened at $78.59 on Friday. The firm has a 50 day moving average of $76.05 and a two-hundred day moving average of $79.36. HealthEquity, Inc. has a 12 month low of $61.81 and a 12 month high of $88.26. The company has a market capitalization of $6.84 billion, a price-to-earnings ratio of 85.42, a P/E/G ratio of 1.19 and a beta of 0.52. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51.

Insider Activity at HealthEquity

In other HealthEquity news, Vice Chairman Stephen Neeleman sold 35,000 shares of the stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the transaction, the insider now directly owns 89,769 shares of the company’s stock, valued at $7,168,952.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Frank Corvino sold 7,705 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $81.89, for a total value of $630,962.45. Following the completion of the sale, the director now directly owns 6,070 shares in the company, valued at $497,072.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the company’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the sale, the insider now directly owns 89,769 shares of the company’s stock, valued at $7,168,952.34. The disclosure for this sale can be found here. In the last 90 days, insiders sold 75,031 shares of company stock valued at $6,103,625. Insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on HQY shares. KeyCorp upped their price target on HealthEquity from $95.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, June 5th. Deutsche Bank Aktiengesellschaft upped their target price on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Barrington Research reissued an “outperform” rating and issued a $105.00 price target on shares of HealthEquity in a research report on Friday, August 30th. Bank of America lowered their price objective on shares of HealthEquity from $105.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Finally, Robert W. Baird increased their target price on shares of HealthEquity from $98.00 to $104.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 4th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $103.83.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.